Our internationalization aims to put our marine-inspired medical advances within every patient’s reach.

PharmaMar is a global oncology company headquartered in Spain. From its inception, the Company has set the goal of growing in excellence, size and reach. This process of international growth is still ongoing with several affiliates across Europe and a subsidiary in the US. We will continue to expand our teams in different regions so we can better address the needs of our stakeholders in every country.

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.

Other Businesses

PharmaMar’s core business is oncology and it fully owns other companies that cover different aspects of healthcare and consumer chemical products.

Awards & Recognition

PhamaMar´s has been awarded and recognized by several institutions and agencies because of its commitment to discovering new marine-derived compounds, to society, to biodiversity, and to its people.